Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
LOS ANGELES, November 20, 2024 BUSINESS WIRE )--Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical collaboration with Eli Lilly and Company (Lilly), a global leader in cardiometabolic health, including diabetes and obesity, to accelerate the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity. Accelerating innovative treatments like this hopefully can make a meaningful impact on the obesity epidemic and the lives of millions of people affected by obesity. Key highlights of the collaboration include: Clinical development of LAE102 through phase 1 study including obese patients Lilly will fund, share resources and expertise to accelerate research and development timelines Laekna retains global rights for LAE102 The collaboration will focus on the development and clinical evaluation of LAE102, an innovative ActRIIA antagonistic mAb that may ha
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025) [Yahoo! Finance]Yahoo! Finance
- Is Now a Good Time to Buy the Dip in Eli Lilly Stock? [Yahoo! Finance]Yahoo! Finance
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance Canada]Yahoo! Finance Canada
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance]Yahoo! Finance
- Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- LLY's page on the SEC website